CXCL12 and peripheral arterial disease: However, in the STOP-PAD trial (SDF-1 plasmid Treatment for Patients with Peripheral Artery Disease; a randomized, double-blind, placebo-controlled clinical trial), the injection of JVS-100, a non-viral DNA plasmid-based therapy encoding SDF-1, did not improve hemodynamic measures or wound healing at 3 months [406].